Sammy Ferri-Borgogno, PHD
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2016 | University of Turin, Turin, Piedmont, IT, Molecular Medicine, Ph.D |
| 2010 | University of Turin, Turin, Piedmont, IT, Medical Biotechnology, M.S |
| 2008 | University of Turin, Turin, Piedmont, IT, Biotechnology, B.S |
Postgraduate Training
| 2019-2021 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2016-2019 | Postgraduate Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - 2024
Editorial Activities
Journal Reviewer, Cancers, 2021 - Present
Journal Reviewer, Journal of Ovarian Cancer Research, 2020 - Present
Journal Reviewer, Theragnostic, 2020 - Present
Journal Reviewer, Scientific Reports, 2020 - Present
Member of Editorial Review Board, Cancers
Honors & Awards
| 2022 | Ovarian Cancer Research Alliance, Liz Tilberis Early Career Award |
| 2020 | Fellowship in Ovarian Cancer Research, The Diane Denson Tobola |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Exploring the 3D tumor-immune ecosystem by multiplexed multiomics. Invited. MD Anderson Special Symposium on Spatialomic Sequencing. Houston, Texas, US.
- 2024. Spatial Biology: Exploring the 3D tumor-immune ecosystem by multiplexed multi-omics. Invited. Research at MD Anderson Town Hall. Houston, Texas, US.
- 2024. Exploring the 3D tumor-immune ecosystem by multiplexed multi-omics. Invited. Spatial biology: Multiplex Multi-omics Seminar. Houston, Texas, US.
- 2024. Simultaneous multiplexed co-detection of RNA and Protein for multi-omic tissue imaging with Imaging Mass Cytometry in Ovarian Cancer. Invited. 2024 Mass Cytometry Texas User Group Meeting. Houston, Texas, US.
- 2023. Spatial multi-omics analysis of the ovarian cancer tumor microenvironment. Invited. Research at MD Anderson Town Hall. Houston, Texas, US.
- 2021. SIO: A SpatioImageOmics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Invited. Research at MD Anderson Town Hall. Houston, Texas, US.
- 2021. Spatially-resolved cellular and transcriptomic analyses of ovarian cancer. Invited. DOD Ovarian Cancer Long-Term Survivors Monthly Meeting, US.
International Presentations
- 2023. When multi-omics meet spatial context: a perfect storm. Invited. Seminar at MBC. Turin, IT.
Grant & Contract Support
| Date: | 2024 - 2029 |
| Title: | 3D Spatial Multi-Omics Profiling of Ovarian Cancer |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Targeting Glutamine in Ovarian Cancer Prevention |
| Funding Source: | The Honorable Tina Brozman Foundation for Ovarian Cancer Research |
| Role: | Co-PI |
| Date: | 2023 - 2024 |
| Title: | Apoe-Lrp5 crosstalk at the tumor-stroma interface modulates immune checkpoint resistance in ovarian cancer |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | BRCA-deficient ovarian cancer and IFITM3: a new “power couple”, |
| Funding Source: | OCRA |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | IFITM3: the key to modulate survival rate in patients with BRCA-deficient ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2021 - 2022 |
| Title: | Imaging Mass Cytometry Spatial Transcriptomics via RNAscope |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2021 - 2024 |
| Title: | Spatially-resolved cellular and transcriptomes analyses of ovarian cancer |
| Funding Source: | OCRA |
| Role: | PI |
| Date: | 2017 - 2021 |
| Title: | Immune checkpoint regulator in ovarian cancer progression |
| Funding Source: | DOD |
| Role: | PI |
| Title: | The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and T Cell Function in Ovarian Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| Title: | Role of the pro-inflammatory omental microenvironment in ovarian cancer progression |
| Funding Source: | NIH |
| Role: | Co-I |
| Title: | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Ng, CW, Wong, KK, Lawson, BC, Ferri-Borgogno, S, Mok, S. Spatial transcriptome reveals histology-correlated immune signature learnt by deep learning attention mechanism on H&E-stained images for ovarian cancer prognosis. Journal of translational medicine 23(1), 2025. e-Pub 2025. PMID: 39856778.
- Ly, C, Veletic, I, Pacheco, CD, Dasdemir, E, Jelloul, FZ, Ferri-Borgogno, S, Basi, A, Gomez, JA, Root, J, Reville, PK, Jindal, S, Basu, S, Sharma, P, Quesada, AE, Bueso-Ramos, CE, Manshouri, T, Cuglievan, B, Garcia, MB, Burks, JK, Abbas, HA. Multimodal spatial proteomic profiling in acute myeloid leukemia. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 40394148.
- Ferri-Borgogno, S, Stolley, D, Gamal, BT, Pacheco, CD, Veletic, I, Basi, A, Mak, D, McAllister, MK, Lin, AJ, Gomez, JA, Casasent, A, Burks, JK. Dual-modality Molecular Cartography. Journal of Visualized Experiments 2025-November(225), 2025. e-Pub 2025. PMID: 41325369.
- Seeley, E, Stolley, D, Casasent, A, Gamal, BT, Ferri-Borgogno, S, Burks, JK. Sequential Detection of Biomolecules in Formalin-fixed, Paraffin-embedded Samples with Mass Spectrometry Imaging. Journal of Visualized Experiments 2025-October(224), 2025. e-Pub 2025. PMID: 41212889.
- Stolley, D, Casasent, A, Gamal, BT, Basi, A, Gui, X, Gomez, JA, Cho, SN, Rocha, L, Li, V, Huynh, T, Ferri-Borgogno, S, Burks, JK. RNA In situ Hybridization with Sequential Protein Immunofluorescence in Tandem Assay. Journal of Visualized Experiments 2025-October(224), 2025. e-Pub 2025. PMID: 41144422.
- Gamal, BT, Stolley, D, Pacheco, CD, Basi, A, Casasent, A, Burks, JK, Ferri-Borgogno, S. MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method. Journal of Visualized Experiments 2025(224), 2025. e-Pub 2025. PMID: 41144547.
- Chowdhury, S, Ferri-Borgogno, S, Yang, P, Wang, W, Peng, J, Mok, S, Wang, P. Learning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic data of ovarian cancer. Briefings in bioinformatics 26(2), 2025. e-Pub 2025. PMID: 40062614.
- Khlebus, E, Vuttaradhi, VK, Ferri-Borgogno, S, Brodsky, AL, Lawson, BC, Mok, S, Hillman, RT. Multiplexed Imaging Mass Cytometry Reveals Tumor-immune Microenvironment–dependent Hormone Receptor Expression in Adult-Type Ovarian Granulosa Cell Tumors. Cancer Research Communications 5(10):1894-1909, 2025. e-Pub 2025. PMID: 41042551.
- Carstens, JL, Krishnan, S, Uppore Kukkillaya, AR, Sorace, AG, Seeley, EH, Ferri-Borgogno, S, Burks, JK. Spatial multiplexing and omics. Nature Reviews Methods Primers 4(1), 2024. e-Pub 2024. PMID: 40880840.
- Ferri-Borgogno, S, Burks, JK, Seeley, EH, McKee, TD, Stolley, D, Basi, A, Gomez, JA, Gamal, BT, Ayyadhury, S, Lawson, BC, Yates, MS, Birrer, MJ, Lu, KH, Mok, S. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses. Cancers 16(5), 2024. e-Pub 2024. PMID: 38473208.
- Carstens JL, Krishnan SN, Rao A, Sorace AG, Seeley EH, Ferri-Borgogno S, Burks JK. Spatial Multiplexing and Omics. Nat Rev Methods Primers 4(1), 2024. e-Pub 2024. PMID: 40880840.
- Han, C, Leonardo, TR, Romana-Souza, B, Shi, J, Keiser, S, Yuan, H, Altakriti, M, Ranzer, MJ, Ferri-Borgogno, S, Mok, S, Koh, TJ, Hong, SJ, Chen, L, DiPietro, LA. Microfibril-associated protein 5 and the regulation of skin scar formation. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 37253753.
- Guimares de Sousa, L, McGrail, DJ, Neto, FL, Li, K, Marques-Piubelli, ML, Ferri-Borgogno, S, Dai, H, Mitani, Y, Burr, NS, Cooper, Z, Kinneer, K, Cortez, MA, Lin, S, Bell, D, Naggar, AE, Burks, JK, Ferrarotto, R. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clinical Cancer Research 29(16):3162-3171, 2023. e-Pub 2023. PMID: 37256648.
- Ferri-Borgogno, S, Zhu, Y, Sheng, J, Burks, JK, Gomez, JA, Wong, KK, Wong, ST, Mok, S. Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors. Cancer Research 83(9):1503-1516, 2023. e-Pub 2023. PMID: 36787106.
- Khlebus, E, Vuttaradhi, VK, Welte, T, Khurana, N, Celestino, J, Beird, H, Gumbs, C, Little, L, Legarreta, A, Fellman, B, Nguyen, T, Lawson, BC, Ferri-Borgogno, S, Mok, S, Broaddus, RR, Gershenson, DM, Futreal, A, Hillman, RT. Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors. Molecular Cancer Research 21(5):483-494, 2023. e-Pub 2023. PMID: 37068116.
- Zhang, L, Au Yeung, CL, Huang, C, Yeung, T, Ferri-Borgogno, S, Lawson, BC, Kwan, SY, Yin, Z, Wong, ST, Thomas, V, Lu, KH, Yip, KP, Sham, JS, Mok, S. Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes. Journal of Experimental and Clinical Cancer Research 41(1), 2022. e-Pub 2022. PMID: 35953818.
- Guimares de Sousa, L, McGrail, DJ, Li, K, Marques-Piubelli, ML, Gonzalez, C, Dai, H, Ferri-Borgogno, S, Godoy, M, Burks, JK, Lin, S, Bell, D, Ferrarotto, R. Spontaneous tumor regression following COVID-19 vaccination. Journal for immunotherapy of cancer 10(3), 2022. e-Pub 2022. PMID: 35241495.
- Chen, Y, Capello, M, Rios Perez, MV, Vykoukal, JV, Roife, D, Kang, Y, Prakash, L, Katayama, H, Irajizad, E, Fleury, A, Ferri-Borgogno, S, Baluya, D, Dennison, JB, Do, K, Fiehn, O, Maitra, A, Wang, H, Chiao, PJ, Katz, MH, Fleming, JB, Hanash, S, Fahrmann, JF. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Molecular Metabolism 56, 2022. e-Pub 2022. PMID: 34971802.
- Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830866.
- Zhu Y, Ferri-Borgogno S, Sheng J, Yeung TL, Burks JK, Cappello P, Jazaeri AA, Kim JH, Han GH, Birrer MJ, Mok SC, Wong STC. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers (Basel) 13(8), 2021. e-Pub 2021. PMID: 33917869.
- Capello M, Fahrmann JF, Rios Perez MV, Vykoukal JV, Irajizad E, Tripathi SC, Roife D, Bantis LE, Kang Y, Kundnani DL, Xu H, Prakash LR, Long JP, Katayama H, Fleury A, Ferri-Borgogno S, Baluya DL, Dennison JB, Aguilar-Bonavides C, Casabar JP, Celiktas M, Do KA, Fiehn O, Maitra A, Wang H, Feng Z, Chiao PJ, Katz MH, Fleming JB, Hanash SM. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol 4:426-436, 2020. e-Pub 2020. PMID: 35050739.
- Ferri-Borgogno S, Barui S, McGee AM, Griffiths T, Singh PK, Piett CG, Ghosh B, Bhattacharyya S, Singhi A, Pradhan K, Verma A, Nagel Z, Maitra A, Gupta S. Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32967217.
- Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, Lu KH, Mok SC, Au-Yeung CL. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32867127.
- Tu B, Yao J, Ferri-Borgogno S, Zhao J, Chen S, Wang Q, Yan L, Zhou X, Zhu C, Bang S, Chang Q, Bristow CA, Kang Y, Zheng H, Wang H, Fleming JB, Kim M, Heffernan TP, Draetta GF, Pan D, Maitra A, Yao W, Gupta S, Ying H. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight 4(21), 2019. e-Pub 2019. PMID: 31557131.
- Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Alvarez H, Bernard V, Ferri-Borgogno S, Brand R, Adler DG, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun 10(1):254, 2019. e-Pub 2019. PMID: 30651550.
- Principe M, Borgoni S, Cascione M, Chattaragada MS, Ferri-Borgogno S, Capello M, Bulfamante S, Chapelle J, Di Modugno F, Defilippi P, Nistico P, Cappello P, Riganti C, Leporatti S, Novelli F. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol 10(1):16, 2017. e-Pub 2017. PMID: 28086938.
- Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, Roux C, Zhou W, Petricoin EF, Cappello P, Novelli F. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget 7(5):5598-612, 2016. e-Pub 2016. PMID: 26734996.
- Bianco M, Aloisi A, Arima V, Capello M, Ferri-Borgogno S, Novelli F, Leporatti S, Rinaldi R. Quartz crystal microbalance with dissipation (QCM-D) as tool to exploit antigen-antibody interactions in pancreatic ductal adenocarcinomadetection. Biosens Bioelectron 42:646-52, 2013. e-Pub 2013. PMID: 23287614.
- Chiriaco MS, Primiceri E, Monteduro AG, Bove A, Leporatti S, Capello M, Ferri-Borgogno S, Rinaldi R, Novelli F, Maruccio G. Towards pancreatic cancer diagnosis using EIS biochips. Lab Chip 13(4):730-4, 2013. e-Pub 2013. PMID: 23287869.
Review Articles
- Ring, K, Mills, AM, Howitt, BE, Grisham, RN, Euscher, ED, Kim, HS, Klopp, AH, Kolin, DL, McCluggage, WG, Mirkovic, J, Park, K, Aoun, E, Awujo, C, Son, J, Mok, S, Ferri-Borgogno, S, Hong, DS, Hoang, L, Jazaeri, AA, How, JA, Lu, KH. Mesonephric-like adenocarcinoma of the female genital tract. Gynecologic oncology 197:57-65, 2025. e-Pub 2025. PMID: 40279981.
- Capello M, Ferri-Borgogno S, Cappello P, Novelli F. alpha-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J 278(7):1064-74, 2011. e-Pub 2011. PMID: 21261815.
Other Articles
- Carstens, JL, Krishnan, S, Rao, A, Sorace, AG, Seeley, EH, Ferri-Borgogno, S, Burks, JK Author Correction. Nature Reviews Methods Primers 4(1), 2024.
- Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, Lu KH, Mok SC, Au-Yeung CL Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436. Cancers (Basel) 13(4), 2021. PMID: 33557446.
Abstracts
- de Sousa LG, Neto FL, McGrail DJ, Li K, Marques-Piubelli ML, Borgogno SF, Dai H, Mitani Y, Lin S, El-Naggar AK, Bell D, Burks J, Ferrarotto R. Single-cell immune mapping of adenoid cystic carcinoma (ACC) reveals potential therapeutic targets for the aggressive solid subtype. 2022 ASCO Annual Meeting(Abstract n. 6090), 2022. e-Pub 2022.
- How JA, Dang M, Ferri-Borgogno S, Euscher E, Yates MS, Peng W, Patel SD, Burks JJ, Vletic I, Gomez J, Lu K, Mok SC, Wang L, Jazaeri AA. Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancer. AACR Annual Meeting 2022, New Orleans, LA(Abstract 1248), 2022. e-Pub 2022.
- Zhu Y, Ferri-Borgogno S, Sheng J, Mok S, Wong S. A multi-omics pipeline for dissecting tumor heterogeneity and its application to prognostic biomarkers discovery in ovarian cancer. Cell-NCI Symposium: Beyond cancer genomics toward precision oncology, 2021. e-Pub 2021.
- Cun HT, Zhu Y, Ferri-Borgogno S, Sheng J, Cheng R, et al. The unique tumor immune microenvironment of clear cell ovarian carcinoma. AACR Virtual Annual Meeting 2021(Abstract 2749), 2021. e-Pub 2021.
- Ferri-Borgogno, Sammy, Jianting S, Ying Z, Wong KK, Wong, ST, Mok SC. Spatially resolved transcriptomics identified distinct tumor-stroma crosstalk networks in long term ovarian cancer survivors. AACR Virtual Annual Meeting, 2021 Abstract 103, 2021. e-Pub 2021.
- Cun HT, Ferri-Borgogno S, Cheng R, Kum J, Han WH, Burks JK, Lu KH, mok SC. The immune landscape of recurrent ovarian carcinoma. AACR Virtual Annual Meeting, 2021(Abstract 2744), 2021. e-Pub 2021.
- Au Yeung CL, Hu W, Ferri-Borgogno S, Tarapore RS, et al. Imipridone ONC206 suppresses ovarian cancer progression through modulating immune cell response. AACR Virtual Annual Meeting, 2021(Abstract 1440), 2021. e-Pub 2021.
- Ferri-Borgogno S, Yeung T, Leung CS, Au Yeung CL, Zhu Y, Wong ST, Mok SC. A novel immune checkpoint regulator in the ovarian cancer microenvironment. AACR Virtual Annual Meeting 2020(Abstract 2232), 2020. e-Pub 2020.
- Zhu Y, Sheng J, Ferri-Borgogno S, Yeung T, Burks JK, Mok S, WOng ST. An artificial intelligence ppeline for imagin mass cytometry data analysis and its application in ovarian cancer prognostic biomarker discover. AACR Virtual Annual Meeting 2020(Abstract 584), 2020. e-Pub 2020.
- Au Yeung CL, Hu W, Zhang L, Ferr-Borgogno S, Tarapore R, Lu K, Mok S. Novel imipridone ONC206 inhibits cell proliferation and induced apoptosis in uterine serous cancer through altering MAPK/AKT signaling network and metabolic reprogramming. AACR Virtual Annual Meeting 2020(Abstract 5321), 2020. e-Pub 2020.
- Au Yeung CL, Hu W, Zhang L, ferri-Borgogno S, Tarapore RS, Allen JE, Lu KH, Mok SC. Identification of a novel biomarker response in a prospective clinical trial of immune checkpoint blockade in recurrent ovarian carcinoma. AAR Virtual Annual Meeting 2020(Abstract 3267), 2020. e-Pub 2020.
- Cun H, Ferri-Borgogno S, Cheng R, Jae-Hoon, Han GH, HLu K, Mok SC. Differential immune landscapes in high-grade serou ovarian tumors of high-risk patients seen by imaging mass cytometry. SGO 2020 Annual Meeting(Abstract 302), 2020. e-Pub 2020.
- Cun H, Cheng J, Ferri-Borgogno S, Kim JH, Han GH, et al. Development of novel biomarkers for early detection of high grade serous ovarian cancer in high risk women using exosomal mRNAs. SGO 202 Annual Meeting, abstract 105, 2020. e-Pub 2020.
- Yeng T, Leung CS, Au Yeung CL, Zhu Y, Wong ST, Mok SC. A novel immune checkpoint regulator in the ovarian cancer microenvironment. AACR-NCI-EORTC Molecular Targets Conference 2019, Boston, MA, 2019. e-Pub 2019.
- Au Yeung CL, Hu W, Zhang L, Ferr-Borgogno S, Tarapore R, Lu K, Mok S. Novel imipridone ONC206 inhibits cell proliferation and induces apoptosis in uterine serous cancer through altering MAPK/AKT/AMPK signaling network and metabolic reprogramming. AACR-NCI-EORTC Molecular Targets Conference 2019, Boston, MA, 2019. e-Pub 2019.
- Tsz-Lun, Leung C, Ferri-Borgogno S, Yip K, Sheng J, Vein L, et al. Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer. AACR-NCI-EORTC Molecular Targets Conference 2019, Boston, MA, 2019. e-Pub 2019.
- Capello M, Fahrman JF, Rios M, Kang Y, Xu H, Ferri-Borgogno S, et al. The role of pancreatic cancer metabolic rewiring in driving the expression of CES2, a predictor of response to FOLFIRINOX therapy. EE-AACR-SIC Special Conference of CES2, Florence, Italy, 2017. e-Pub 2017.
- M, Capello, Fahmann JF, Rios M, Kang Y, Xu H, Ferri-Borgogno S, et al. The role of pancreatic cancer metabolic rewiring in driving the expression of CES2, a predictor of response to FOLFIRINOX therapy. EACR-AACR-SIC Special Conferfence 2017, Florence Italy, 06/2017, 2017. e-Pub 2017.
- M, Capello, Fahmann JF, Rios M, Kang Y, Xu H, Ferri-Borgogno S, etc. The role of pancreatic cancer metabolic rewiring in driving the expression of CES2, a predictor of response to FOLFIRINOX therapy. 85 EAS Congress, Prague, Czech Republic, 2017. e-Pub 2017.
- Ferri-Borgogno S, Reisenauer MR, Gupta AK, Maitra A, Gupta S. Synthetic vulnerabilities in MLL3 deficient pancreatic tumors. Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer. AACR Cancer, San Diego, CA, USA, 2017. e-Pub 2017.
- Moitza P, Ceruti P, Borgono S, Capello M, Chattaragada MS, Ferrit-Borgogno S, Rolla S, Conti L, Bestagno M, Zentilin L, Migliorini P. Targeting of surface ENO1 inhibits the invasiveness of pancreatic cancer cells. SIICA "Giornata nazionale dei dottorati di immunologiea", Bari, Italy, 2014. e-Pub 2014.
- Capello M, Ferri-Borgogno S, Moitza Principe MS, Chattaragada CR, Zhou W, Folia L, Liotta LA, Petricoin EF, III, Cappelli P, Novelli F. Identification of early pancreatic cancer-associated autoantibodies in mouse and human. AACR Special Conference in Pancreatic Cancer: Innovations in Research and Treatment, Hyatt Regency, New Orleans, LA, USA, 2014. e-Pub 2014.
- Capello M, Ferri-Borgogno S, Principe M, Chattaragada MS, Riganti C, Zhou W, Follia L, Liotta LA, Emanuel F Petricoin III, Cappell P, Novelli F. Alpha-enolase knockdown reprograms metabolism and points out targetable pathways to counteract PDA growth. AACR Special Conference in Pancreatic Cancer: Innovations in Research and Treatment, Hyatt Regency New Orleans, New Orleans, LA, USA, 2014. e-Pub 2014.
- Cappello M, Ferri-Borgogno S, Cappello P, Zhou W, Mandili G, Speruditi I, Maruccio G, Milella M, Novelli FChiarle R, Scarpa A, Pederzoli P, Nistico P, Milella M, NOvelli F. Identification of early pancreatic cancer-associated autoantibodies in mouse and human. 15th International Congress of Immunology, Milano, Italy, 2013. e-Pub 2013.
- Sammy F, Michela C, Paola C, Weidong Z, Giorgia M, Isabella S, Giuseppe M, Michele M, Francesco N. Characterization of circulating autoantibodies to post-translationally modified a-Enolase in pancreatic cancer. 1st Pancreatic Cancer Meeting, Salemo, Italy, 2013. e-Pub 2013.
- Capello M, Principe M, Chattaragada MS, Riganti C, Zhou W, s F, Rolla S, Liotta LA, Petricoin EF, Cappello P, NOvelli F. Can the moonlighting glycolytic enzyme a-enolase be a therapeutic target in pancreatic cancer?. 1st Pancreatic Cancer Meeting, Salemo, Italy, 2013. e-Pub 2013.
- Capello M, Principe M, Chattaragada MS, Riganti C, Zhou W, s F, Rolla S, Liotta LA, Petricoin EF, Cappello P, NOvelli F. Can the moonlighting glycolytic enzyme a-enolase as a therapeutic target in pancreatic cancer?. American Association for Cancer Research Annual Meeting 2013, Washington DC, USA, 2013. e-Pub 2013.
- Capello M, Principe M, Chattaragada MS, Riganti C, Zhou W, s F, Rolla S, Liotta LA, Petricoin EF, Cappello P, Novelli F. The moonlighting glycolytic enzyme a-enolase be a therapeutic target in pancreatic cancer. Tumor Metabolism, Keystone Symposia, Keystone, CO, USA, 2013. e-Pub 2013.
- Capello M, Cappello P, Ferri-Borgogno S, Zhou W, Mandili G, Fredolini C, Sperduti I, Linty FC, Perticoin E, Milella M, Novelli F. Autoantibody signature in pancreatic ductal adenocarcinoma. Pancreatic Cancer: Progress and Challenges, American Association for Cancer Research Special Conference, Lake Tahoe, NV, USA, 2012. e-Pub 2012.
- Cappello M, Cappello P, Linty FC, Ferri-Borgogno S, Chiarle R, Scarpa A, Pederzoli P, Nistico P, Milella M, NOvelli F. Mouse to human autoantibody signature in pancreatic ductal adenocarcinoma. 10th Annual world congress of the human proteome organization, Geneva, Switzerland, 2011. e-Pub 2011.
- Cappello M, Cappello P, Linty FC, Ferri-Borgogno S, Chiarle R, Scarpa A, Pederzoli P, Nistico P, Milella M, Novelli F. Mouse to human autoantibody signature in pancreatic ductal adenocarcinoma. 6th Italian Proteomics Association Annual National Congress, Torino, Italy, 2011. e-Pub 2011.
Patient Reviews
CV information above last modified July 22, 2026